C-Path receives COA qualification from FDA for the non-small cell lung cancer SAQ
TUCSON, Ariz. - May 7, 2018 -- Critical Path Institute's (C-Path) Patient-Reported Outcome (PRO) Consortium announces its second clinical outcome assessment (COA) qualification from the...





